- Home
- NDRA
NDRA
ENDRA Life Sciences Inc.
as 04-03-2025 4:00pm EST
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | N/A | IPO Year: | 2017 |
| Target Price: | $14000.00 | AVG Volume (30 days): | 7.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -56.94 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.15 - $700.00 | Next Earning Date: | 03-31-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ENDRA Life Sciences Inc. News
NDRA Breaking Stock News: Dive into NDRA Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies
Business Wire
4 days ago
ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update
Zacks
2 months ago
What Makes ENDRA Life Sciences (NDRA) a New Strong Buy Stock
Business Wire
4 months ago
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Business Wire
5 months ago
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Business Wire
5 months ago
Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting® 2024
Business Wire
5 months ago
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
MT Newswires
5 months ago
Sector Update: Health Care Stocks Softer Late Afternoon
Compare NDRA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NDRA ENDRA Life Sciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.